RTP Mobile Logo
Meet The Professors: Management of Chronic Lymphocytic Leukemia (Audio Program)
Released May 2021

Featuring a roundtable discussion with Drs Ian W Flinn, John M Pagel and Tanya Siddiqi. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    These activities are intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of chronic lymphocytic leukemia (CLL).

    LEARNING OBJECTIVES

    • Individualize the selection of systemic therapy for patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL), considering clinical presentation, biomarker profile, coexisting medical conditions, psychosocial status and, where applicable, prior therapeutic exposure.​
    • Recognize the superior efficacy and safety of Bruton tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for CLL, and discern how this strategy can be optimally integrated into nonresearch treatment.​
    • Compare and contrast the efficacy and safety of approved BTK inhibitors for the treatment of CLL to identify patients for whom each of these agents may be appropriate.​
    • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and determine how to appropriately integrate this regimen into current clinical practice.​
    • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies in the management of CLL.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MTPCLL21/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/MTPCLL21/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MTPCLL21/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/MTPCLL21.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Presenting Faculty Members

    Ian W Flinn, MD, PhD
    Director of Lymphoma Research Program
    Sarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee

    Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Gilead Sciences Inc, Great Point Partners LLC, Iksuda Therapeutics, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, MorphoSys, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, ScienceCurio, Seagen Inc, Takeda Oncology, Unum Therapeutics, Verastem Inc, Vincere Biosciences Inc, YL-Pharma Co Ltd; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Calithera Biosciences, Celgene Corporation, Constellation Pharmaceuticals, Curis Inc, F Hoffmann-La Roche Ltd, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MorphoSys, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Roche Laboratories Inc, Seagen Inc, Takeda Oncology, Teva Oncology, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Research & Development Corp, Unum Therapeutics, Verastem Inc.

    John M Pagel, MD, PhD
    Chief of Hematologic Malignancies
    Center for Blood Disorders and Stem Cell Transplantation
    Swedish Cancer Institute
    Seattle, Washington

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Epizyme Inc, Gilead Sciences Inc, MorphoSys, Seagen Inc.

    Tanya Siddiqi, MD
    Associate Professor
    Director, Chronic Lymphocytic Leukemia Program
    Department of Hematology and Hematopoietic Cell Transplantation
    City of Hope National Medical Center
    Duarte, California

    Advisory Committee: Celgene Corporation, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Board/Committee: BeiGene Ltd; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company.

    Contributing General Medical Oncologists

    Gigi Chen, MD
    Diablo Valley Oncology and Hematology Medical Group
    Pleasant Hill, California

    No relevant conflicts of interest to disclose.

    Ranju Gupta, MD
    Attending Physician
    Co-Director, Cardio-Oncology Program
    LVPG Hematology Oncology Associates
    Lehigh Valley Health Network
    Bethlehem, Pennsylvania

    Speakers Bureau: Lilly.

    Laurie Matt-Amaral, MD, MPH
    Attending Physician
    Cleveland Clinic Akron General Medical Center
    Akron, Ohio

    Speakers Bureau: Bristol-Myers Squibb Company.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc and AstraZeneca Pharmaceuticals LP.

    Release date: May 2021
    Expiration date: May 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):